Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.
University of Rochester Medical CenterOct 28 2024 Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus vaccines. In a recent commentary in The Lancet, Angela Branche, MD, an infectious diseases researcher at the University of Rochester Medical Center , details what has been learned during the vaccine's first season.
Vaccines protect against severe symptoms and keep people out of the hospital In 2023, the FDA approved three RSV vaccines for older adults. Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing RSV pneumonia and bronchitis in more than 80 percent of participants.
Related StoriesHowever, the uptake of the RSV vaccine in the 2023-2024 winter season was low. An estimated 24 percent of US adults aged 60 years and older received the vaccine, compared to influenza vaccination rates, which approach 50 percent each year for the same group.
Flu Hospital Infectious Diseases Influenza Respiratory Respiratory Illness Respiratory Syncytial Virus Vaccine Virus
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Everything NHS has said about 'tripledemic' and what people should doThe RSV, flu and Covid viruses are doing the rounds
Read more »
Real world data highlights effectiveness of RSV vaccineA multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- short for respiratory syncytial virus -- vaccine.
Read more »
XEC Covid variant 'don't wait' warning amid winter 'tripledemic' fearsThe NHS is warning against a 'tripledemic' of viruses this winter, including Covid, flu and RSV
Read more »
Surge in killer lung virus fuels ‘tripledemic’ fears – as new threat emerges ‘targeting the young’...What is RSV (Respiratory Syncytial Virus) or bronchiolitis?
Read more »
Inside RSV: Researchers pinpoint markers of more severe casesRespiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory issues like bronchiolitis and pneumonia. However, the reasons why some children experience only mild symptoms while others suffer from severe disease are not well understood.
Read more »
Research links NK cells to severe cases of RSV in childrenRespiratory syncytial virus (RSV) is the leading cause of hospitalization in young children due to respiratory complications such as bronchiolitis and pneumonia.
Read more »